Imatinib Mesylate (Gleevec)

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Also Known As:

Networked: 9991 relevant articles (1458 outcomes, 1426 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Cortes, Jorge: 174 articles (01/2020 - 05/2002)
2.	Kantarjian, Hagop: 149 articles (12/2023 - 01/2000)
3.	Hochhaus, Andreas: 132 articles (05/2024 - 02/2002)
4.	Baccarani, Michele: 102 articles (01/2021 - 02/2002)
5.	Saglio, Giuseppe: 96 articles (05/2024 - 02/2002)
6.	Breccia, Massimo: 94 articles (09/2023 - 04/2004)
7.	Kantarjian, Hagop M: 91 articles (05/2024 - 03/2002)
8.	Druker, Brian J: 89 articles (11/2023 - 01/2002)
9.	O'Brien, Susan: 88 articles (01/2018 - 05/2002)
10.	Cortes, Jorge E: 79 articles (05/2024 - 07/2002)

Related Diseases

1.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 12/01/2023 - "Due to its remarkable efficacy in producing hematologic, cytogenetic, and molecular remissions, the FDA approved Imatinib as the first-line treatment for newly diagnosed Chronic Myeloid Leukemia (CML) patients. " 01/01/2023 - "Imatinib is highly effective in the treatment of chronic myelogenous leukemia (CML), but the primary and acquired imatinib resistance remains the big hurdle. " 01/01/2022 - "The prognosis of chronic myelogenous leukemia (CML-CP) in chronic phase has improved dramatically since the introduction of imatinib. " 01/01/2020 - "Imatinib mesylate (IM) is highly efficacious in the treatment of chronic myeloid leukemia (CML). " 01/01/2019 - "Imatinib has shown to be highly efficacious in the treatment of chronic myeloid leukemia (CML) but continuous dosing and patient adherence is essential treatment success. "
2.	Neoplasms (Cancer) 04/01/2006 - "The most effective treatment for unresectable tumors is imatinib mesylate, based on two phase II trials. " 01/01/2013 - "Thus, imatinib inhibits multiple novel chemoresistance pathways, which indicates that it may be effective in reversing intrinsic and acquired resistance in cancers containing highly active c-Abl and Arg, a critical step in effectively treating metastatic disease. " 09/01/2007 - "We report here two patients with metastatic GIST who developed pelvic bone marrow focal lesions visible on MRI examinations, while Imatinib dramatically improved other tumor sites. " 09/01/2006 - "Our best estimate is that patients receiving imatinib who have a complete cytogenetic remission have a higher projected probability of 10-year survival than patients who are transplanted, based on results provided by the CIBMTR, and have about the same probability compared to the data from the Fred Hutchinson Cancer Center for patients in the 30- to 60-year-old range. " 01/01/2003 - "Primary isolated tumors are best treated by surgery; metastatic or recurrent forms have recently shown dramatic improvement with STI 571."
3.	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 07/01/2017 - "After identification of activating mutations of the KIT gene in gastrointestinal stromal tumor (GIST)-the most common sarcomaof the gastrointestinal tract-a phase 2 study demonstrated efficacy of imatinib mesylate in patients with metastatic GIST harboring a KIT exon 11 mutation. " 01/01/2023 - "Imatinib mesylate (IM) is highly effective in the treatment of gastrointestinal stromal tumors (GISTs). " 01/01/2023 - "Imatinib is the standard first-line treatment for advanced gastrointestinal stromal tumors (GISTs); however, most patients eventually develop imatinib resistance, leading to considerable clinical challenges. " 04/01/2022 - "Although imatinib has dramatically improved the outcomes of patients with gastrointestinal stromal tumor (GIST), marked inter-individual differences in its efficacy and toxicity have been observed. " 03/13/2017 - "Imatinib mesylate (IM) has dramatically improved the outcomes of gastrointestinal stromal tumor (GIST) patients. "
4.	Philadelphia Chromosome 01/01/2010 - "From May 2005 to September 2009, we treated 42 patients (40 years; range 16-69) with Philadelphia chromosome (Ph+) positive in chronic phase CML with oral imatinib mesylate at daily doses of 400 mg. Overall survival (OS) and frequency of complete or major cytogenetic remission (CCR/MCR) were evaluated. " 05/01/2012 - "All 1,063 patients selected met the following inclusion criteria: aged 18 or older and in chronic phase at the time of diagnosis, Philadelphia chromosome and/or BCR-ABL positive, received first-line treatment with imatinib, and not enrolled in a randomized clinical trial during the period of retrospective review. " 01/01/2020 - "One thousand five hundred and ten imatinib-treated patients with Philadelphia-chromosome-positive (Ph+) CML randomized in CML-study IV were analyzed for ACA/Ph+ and blast increase. " 01/01/2015 - "On the basis of 1151 Philadelphia chromosome positive chronic phase patients of the randomized CML-study IV, we examined the incidence of newly arising ACA under imatinib treatment with regard to the p210BCR-ABL breakpoint variants b2a2 and b3a2. " 01/01/2013 - "DESIGN, PATIENTS, AND INTERVENTION: This study assessed the effects of high-dose (600 mg/d) imatinib on bone parameters in newly diagnosed chronic-phase Philadelphia chromosome-positive CML patients (n = 11) enrolled in the TIDEL II study. "
5.	Leukemia 04/01/2015 - "Although imatinib is an effective treatment for CML and most patients treated with imatinib do attain some form of remission, imatinib does not completely eradicate all leukemia cells, and if treatment is stopped, all patients eventually relapse (Cortes, 2005). " 01/01/2004 - "Although Imatinib, the first molecularly targeted drug developed for CML has achieved a remarkable success, the emergence of resistance to this agent mitigates the prospect of a cure for this leukemia. " 07/01/2015 - "The patient was treated with imatinib and achieved complete clinical remission of his leukemia and the GEH. " 11/01/2008 - "Treatment with imatinib is very effective in Bcr-Abl positive leukemia. " 05/01/2011 - "The simulations presented in this paper imply that treatment programs that involve strategic treatment interruptions may prevent leukemia from relapsing and may prevent remission for significantly longer than continuous imatinib treatment. "

Related Drugs and Biologics

1.	Tyrosine Kinase Inhibitors
2.	Imatinib Mesylate (Gleevec)
3.	nilotinib
4.	Dasatinib (BMS 354825)
5.	Phosphotransferases (Kinase)
6.	bcr-abl Fusion Proteins
7.	Sunitinib (Sutent)
8.	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
9.	Protein-Tyrosine Kinases (Tyrosine Kinase)
10.	Interferons

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Stem Cell Transplantation
4.	Aftercare (After-Treatment)
5.	Hematopoietic Stem Cell Transplantation